| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial.
|
Biol Psychiatry
|
2007
|
5.59
|
|
2
|
Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial.
|
J Clin Psychiatry
|
2002
|
3.47
|
|
3
|
Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice.
|
Depress Anxiety
|
2012
|
2.23
|
|
4
|
Transcranial magnetic stimulation in the treatment of major depressive disorder: a comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment.
|
J Clin Psychiatry
|
2008
|
1.89
|
|
5
|
Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression.
|
J Psychiatr Res
|
2002
|
1.78
|
|
6
|
Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.
|
J Clin Psychiatry
|
2002
|
1.67
|
|
7
|
Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine.
|
J Clin Psychopharmacol
|
2004
|
1.65
|
|
8
|
Linking disease symptoms and subtypes with personalized systems-based phenotypes: a proof of concept study.
|
Brain Behav Immun
|
2012
|
1.53
|
|
9
|
Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome.
|
Brain Behav Immun
|
2004
|
1.44
|
|
10
|
Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
|
Eur Neuropsychopharmacol
|
2004
|
1.40
|
|
11
|
Effects of duloxetine on painful physical symptoms associated with depression.
|
Psychosomatics
|
2004
|
1.21
|
|
12
|
Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study.
|
Brain Stimul
|
2010
|
1.07
|
|
13
|
Transcranial magnetic stimulation in the acute treatment of major depressive disorder: clinical response in an open-label extension trial.
|
J Clin Psychiatry
|
2008
|
1.01
|
|
14
|
A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow-up period.
|
J Clin Psychiatry
|
2014
|
0.86
|
|
15
|
Cost-effectiveness of transcranial magnetic stimulation in the treatment of major depression: a health economics analysis.
|
Adv Ther
|
2009
|
0.84
|
|
16
|
The NeuroStar TMS device: conducting the FDA approved protocol for treatment of depression.
|
J Vis Exp
|
2010
|
0.80
|
|
17
|
Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of quality of life outcome measures in clinical practice.
|
CNS Spectr
|
2013
|
0.79
|
|
18
|
Reply regarding "efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial".
|
Biol Psychiatry
|
2010
|
0.78
|
|
19
|
Left dorsolateral prefrontal transcranial magnetic stimulation (TMS): sleep factor changes during treatment in patients with pharmacoresistant major depressive disorder.
|
Psychiatry Res
|
2012
|
0.77
|
|
20
|
The tyramine pressor test may have limited sensitivity, especially in the presence of dual serotonin/norepinephrine uptake inhibition.
|
Neuropsychopharmacology
|
2002
|
0.77
|
|
21
|
Benefit and Risk Evaluation of Biased μ-Receptor Agonist Oliceridine versus Morphine.
|
Anesthesiology
|
2020
|
0.75
|